Combo Immunotherapy Outperforms Monotherapy in Cancer Trial NSCLC
Translational findings and higher major pathological response support combinations over monotherapy before surgery for Non-Small Cell Lung Cancer
Paper on “Combination immunotherapy” with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small cell lung cancer (NSCLC), according to researchers at The University of Texas MD Anderson Cancer Center. The findings, published recentlyin Cancer Discovery, were first presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.
RESULTS
Participants
Between March 20, 2019, and September 21, 2020, a total of 84 patients with stage IA3–IIIA NSCLC ( from AJCC 8th edition) were enrolled in 17 study centers across seven countries (Canada, France, Italy, Portugal, Spain, Switzerland, and the United States). The study design is shown in Fig. 1A. Among 84 enrolled patients, 83 received study treatment. Twenty-seven patients were randomized to durvalumab monotherapy, 21 to durvalumab + oleclumab, 20 to durvalumab + monalizumab, and 16 to durvalumab + danvatirsen. The treatment in each arm was administered over a 4-week period prior to the planned surgery.
